Recent performance snapshot

KalVista Pharmaceuticals (KALV) has drawn fresh attention after a strong stretch for the stock, with the price at US$26.87 and total return figures over the past year and past 3 months standing out.

For context, the share price has shown strong momentum over the past year, with a 90 day share price return of 67.31% and a 1 year total shareholder return of 127.71%. However, the 5 year total shareholder return of 1.66% suggests much more muted gains over a longer horizon.

If KalVista's run has you thinking about where else strong trends might emerge in healthcare related technology, this is a good moment to scan 40 healthcare AI stocks.

With KalVista reporting revenue of US$114.48 million alongside a loss of US$135.94 million, plus a large indicated intrinsic discount, it is fair to ask: is this an overlooked opportunity or already pricing in future growth?

Most Popular Narrative: 13.3% Undervalued

KalVista's most followed narrative puts fair value at $31.00 per share, compared with the last close at $26.87, which frames the recent rally against a higher long term target.

International rollout, including launches in the U.S. and Germany and approvals in the U.K., EU, Switzerland and Australia, together with planned launches in the U.K. and Japan in 2026, broadens the addressable market. This can influence total revenue and help spread fixed operating costs over a larger sales base.

Want to see what is behind that fair value gap? The narrative focuses on steep revenue expansion, rising margins and a rich earnings multiple several years from now. The full set of assumptions, including the discount rate and expected profitability path, is presented together for closer review.

Result: Fair Value of $31.00 (UNDERVALUED)

However, there are still real pressure points, including EKTERLY uptake potentially normalizing from high burden patients and heavy SG&A spending relative to current EKTERLY sales.

Another way to look at valuation

So far, the story has leaned on analyst targets and a fair value of $31.00, which suggests KalVista might be 13.3% undervalued. The market picture looks different when you focus on the current P/S of 12.5x, which is higher than both the estimated fair ratio of 5.9x and the US Biotechs average of 10.9x. That gap points to meaningful valuation risk if growth or sentiment softens. Which signal do you think deserves more weight right now?

Next Steps

Looking at this mix of optimism and concern, it helps to move quickly, review the numbers for yourself and decide what really matters. To weigh up both sides in one place, start with the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If KalVista has sparked fresh thinking about your portfolio, do not stop here. The broader market is full of other opportunities that could better match your goals.

• Target stronger balance sheets by scanning companies in the solid balance sheet and fundamentals stocks screener (46 results) that may handle shocks more comfortably.
• Hunt for potential value by reviewing the 46 high quality undervalued stocks that combine quality fundamentals with prices that look out of sync with their financials.
• Get ahead of the crowd by checking the screener containing 22 high quality undiscovered gems before other investors start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.